Metastatik Pankreas KanserindeNötrofil/Lenfosit Oranının Prognostik Önemi

GİRİŞ ve AMAÇ: Çeşitli kanser tiplerinde yüksek nötrofillenfosit oranının (NLO) kötü sağkalım sonuçları ile ilişkili olduğu bildirilmektedir. Çalışmamızda metastatik pankreas kanserli hastalarda NLO'nunprognostik önemini değerlendirmeyi amaçladık. YÖNTEM ve GEREÇLER: Ocak 2013 ile Aralık 2014 tarihleri arasında, metastatik pankreas karsinomu tanısı alan 40 hasta retrospektif olarak incelendi. Hastalarda NLO ile genel sağkalım (OS) ve progresyonsuz sağkalım (PFS) ilişkisi Kaplan-Meier metodu kullanılarak analiz edildi. BULGULAR: Çalışmaya dahil edilen 40 hastanın ortanca yaşı 58.5 olup, %75 i erkekti. Hastaların 21'inde (%52.5) yüksek NLO (>=3.45) saptandı. Nötrofil/lenfosit oranı hem OS hem de PFS için önemli bir prognostik paremetre idi. Ortanca OS NLO yüksek ve normal hastalarda sırası ile 2.8 ay ve 11.1 ay (P

Prognostic Significance of The Neutrophil-to-Lymphocyte Ratio in Metastatic Pancreatic Cancer

INTRODUCTION: Innumeroustypes of malignancy it is reported that high neutrophil-to-lymphocyte ratio (NLR) is associated with poor outcomes. We aimed to investigate the prognostic significance of NLR in patients with metastatic pancreatic cancer in our study. METHODS: Between January 2013 and December 2014, 40 patients with metastatic pancreas carcinoma were retrospectively reviewed. The association of NLR with progression-free survival (PFS) and overall survival (OS) was analyzed using the Kaplan–Meier method. RESULTS: Forty patients were included in this study. The median age of patients was 58.5 years (range 44–80 years) and the majority ofpatients were male (75.0%). High NLR (≥3.45) were obtained in 21 patients. NLR was a significant prognostic factor for both OS and PFS. The median OS for patients with highand normal NLR was2.8 and 11.1 months, respectively (p

PDF

___

1. Michaud DS. Epidemiology of pancreatic cancer. Minerva chirurgica. 2004;59:99-111.
2. Sharma C, Eltawil KM, Renfrew PD, Walsh MJ, Molinari M. Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010. World journal of gastroenterology. 2011;17:867-97.
3. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378:607-20.
4. Chiang KC, Yeh CN, Ueng SH et al. Clinicodemographic aspect of resectable pancreatic cancer and prognostic factors for resectable cancer. World journal of surgical oncology. 2012;10:77.
5. Boeck S, Stieber P, Holdenrieder S, Wilkowski R, Heinemann V. Prognostic and therapeutic significance of carbohydrate antigen 19- 9 as tumor marker in patients with pancreatic cancer. Oncology. 2006;70:255-64.
6. Demirci NS, Dogan M, Erdem GU et al. Is plasma caveolin-1 level a prognostic biomarker in metastatic pancreatic cancer? Saudi journal of gastroenterology: official journal of the Saudi Gastroenterology Association. 2017;23:183-9.
7. Duffy MJ, Sturgeon C, Lamerz R et al. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Annals of oncology: official journal of the European Society for Medical Oncology. 2010;21:441-7.
8. Pine JK, Fusai KG, Young R et al. Serum Creactive protein concentration and the prognosis of ductal adenocarcinoma of the head of pancreas. European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2009;35:605-10.
9. Luo G, Guo M, Liu Z et al. Blood neutrophillymphocyte ratio predicts survival in patients with advanced pancreatic cancer treated with chemotherapy. Annals of surgical oncology. 2015;22:670-6.
10. Martin HL, Ohara K, Kiberu A, Van Hagen T, Davidson A, Khattak MA. Prognostic value of systemic inflammation-based markers in advanced pancreatic cancer. Internal medicine journal. 2014;44:676-82.
11. Teo M, Mohd Sharial MS, McDonnell F, Conlon KC, Ridgway PF, McDermott RS. Prognostic role of neutrophil-to-lymphocyte ratio in advanced pancreatic ductal adenocarcinoma: impact of baseline fluctuation and changes during chemotherapy. Tumori. 2013;99:516-22.
12. Xue P, Kanai M, Mori Y et al. Neutrophilto-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients. Cancer medicine. 2014;3:406-15.
13. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883-99.
14. Jass JR. Lymphocytic infiltration and survival in rectal cancer. Journal of clinical pathology. 1986;39:585-9.
15. Kusumanto YH, Dam WA, Hospers GA, Meijer C, Mulder NH. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis. 2003;6:283-7.
16. Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava E, Kosma VM. Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. The Journal of pathology. 1997;182:318-24.
17. Waldner M, Schimanski CC, Neurath MF. Colon cancer and the immune system: the role of tumor invading T cells. World journal of gastroenterology. 2006;12:7233-8.
18. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331:1565-70.
19. Bhatti I, Peacock O, Lloyd G, Larvin M, Hall RI. Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophillymphocyte versus platelet-lymphocyte ratio. American journal of surgery. 2010;200:197-203.
20. Han S, Liu Y, Li Q, Li Z, Hou H, Wu A. Pre-treatment neutrophil-to-lymphocyte ratio is associated with neutrophil and T-cell infiltration and predicts clinical outcome in patients with glioblastoma. BMC cancer. 2015;15:617.
21. Malietzis G, Giacometti M, Askari A et al. A preoperative neutrophil to lymphocyte ratio of 3 predicts disease-free survival after curative elective colorectal cancer surgery. Annals of surgery. 2014;260:287-92.
22. Mano Y, Shirabe K, Yamashita Y et al. Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival after hepatectomy for hepatocellular carcinoma: a retrospective analysis. Annals of surgery. 2013;258:301-5.
23. Paramanathan A, Saxena A, Morris DL. A systematic review and meta-analysis on the impact of pre-operative neutrophil lymphocyte ratio on long term outcomes after curative intent resection of solid tumours. Surgical oncology. 2014;23:31-9.
24. Viers BR, Boorjian SA, Frank I et al. Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy. European urology. 2014;66:1157-64.
25. Yao M, Liu Y, Jin H et al. Prognostic value of preoperative inflammatory markers in Chinese patients with breast cancer. Onco Targets and therapy. 2014;7:1743-52.
26. Zhao QT, Yang Y, Xu S et al. Prognostic role of neutrophil to lymphocyte ratio in lung cancers: a meta-analysis including 7,054 patients. OncoTargets and therapy. 2015;8:2731-8.